A Three-Arm Randomized Controlled Study Comparing Patient-Reported Outcomes in People With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion or Multiple Daily Injections
Authors' conclusion
This study showed that switching from MDI to CSII improves both psychosocial well-being and physiological outcomes. Furthermore, there were no substantial differences between the established and the recently released patch pump.
Study context
- Population
- People with T1D on MDI therapy142 completed
- Participants
- 181 people
- Comparison
- Continuous subcutaneous insulin infusion (CSII) with Solo or Omnipod patch pump vs MDI
- MDIn = 61reference
- Solon = 62
- Omnipodn = 58
- Primary endpoint
- Patient-reported outcomes (PROs) assessed with the diabetes technology questionnaire (DTQ) "change" score
- Follow-up
- 26 weeks
Methodological detailsthree-arm, Weeks 26 to 39: all participants used CSII with Solo
- Three-arm
- Weeks 26 to 39: all participants used CSII with Solo
Primary result
As reported in the abstract
DTQ "change" score (baseline-adjusted mean)
Solo
105.9
baseline-adjusted mean · 95% CI 100.6–111.2
MDI
94.8
baseline-adjusted mean · 95% CI 89.6–100.0
Solo vs MDI: P = 0.001 · Solo vs Omnipod: P = 0.382
Further findings
| Outcome | MDI | Solo | Omnipod | P value |
|---|---|---|---|---|
| HbA1c change · 26 weeksSolo vs MDI · significant difference | 0.2 ± 0.7 % | −0.2 ± 0.8 % | −0.1 ± 0.8 % | P = 0.009 |
| HbA1c change · 26 weeksSolo vs Omnipod · not significant | P = 0.896 |
- HbA1c change: HbA1c increased with MDI and decreased in both pump groups
Original publication
A Three-Arm Randomized Controlled Study Comparing Patient-Reported Outcomes in People With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion or Multiple Daily Injections. J Diabetes Sci Technol. Published 8 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →